Fidelity Investments’s ANI Pharmaceuticals ANIP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.05M Buy
36,848
+18,071
+96% +$1.45M ﹤0.01% 2608
2026
Q1
$1.44M Buy
18,777
+8,920
+90% +$696K ﹤0.01% 2741
2025
Q4
$778K Sell
9,857
-25,237
-72% -$2.19M ﹤0.01% 2944
2025
Q3
$3.21M Buy
35,094
+31,459
+865% +$2.57M ﹤0.01% 2382
2025
Q2
$237K Buy
3,635
+59
+2% +$3.84K ﹤0.01% 3247
2025
Q1
$239K Buy
3,576
+485
+16% +$29K ﹤0.01% 3177
2024
Q4
$171K Sell
3,091
-15,310
-83% -$879K ﹤0.01% 3330
2024
Q3
$1.1M Buy
18,401
+3,972
+28% +$242K ﹤0.01% 2569
2024
Q2
$919K Buy
14,429
+13,885
+2,552% +$901K ﹤0.01% 2546
2024
Q1
$37.6K Buy
544
+50
+10% +$3.02K ﹤0.01% 3732
2023
Q4
$27.3K Buy
494
+3
+0.6% +$165 ﹤0.01% 3795
2023
Q3
$28.5K Buy
491
+35
+8% +$2.02K ﹤0.01% 3632
2023
Q2
$24.5K Buy
456
+161
+55% +$7.14K ﹤0.01% 3751
2023
Q1
$11.7K Buy
295
+13
+5% +$548 ﹤0.01% 4067
2022
Q4
$11.3K Sell
282
-72
-20% -$2.7K ﹤0.01% 3966
2022
Q3
$11K Buy
354
+266
+302% +$9.11K ﹤0.01% 4043
2022
Q2
$2K Sell
88
-49
-36% -$1.41K ﹤0.01% 4526
2022
Q1
$4K Buy
+137
New +$5.11K ﹤0.01% 4471
2021
Q3
Sell
-12
Closed 4292
2021
Q2
$0 Buy
+12
New +$408 ﹤0.01% 4195
2021
Q1
Sell
-246
Closed -$7K 3949
2020
Q4
$7K Sell
246
-27
-10% -$773 ﹤0.01% 3370
2020
Q3
$8K Buy
273
+27
+11% +$804 ﹤0.01% 3214
2020
Q2
$8K Hold
246
﹤0.01% 3153
2020
Q1
$10K Sell
246
-764
-76% -$40.6K ﹤0.01% 3106
2019
Q4
$62K Sell
1,010
-3
-0.3% -$199 ﹤0.01% 2847
2019
Q3
$74K Buy
1,013
+1
+0.1% +$75 ﹤0.01% 2794
2019
Q2
$83K Buy
1,012
+12
+1% +$853 ﹤0.01% 2774
2019
Q1
$71K Hold
1,000
﹤0.01% 2725
2018
Q4
$45K Buy
+1,000
New +$52.4K ﹤0.01% 2743
2016
Q2
Sell
-84,400
Closed -$2.84M 2649
2016
Q1
$2.84M Buy
+84,400
New +$2.86M ﹤0.01% 2299
2015
Q3
Sell
-55,700
Closed -$3.46M 2715
2015
Q2
$3.46M Buy
55,700
+10,500
+23% +$625K ﹤0.01% 2333
2015
Q1
$2.83M Buy
+45,200
New +$2.75M ﹤0.01% 2361

Other funds holding ANIP

Fidelity Investments's ANIP Position: Q2 2026 in Review

Fidelity Investments increased its ANI Pharmaceuticals (ANIP) stake by 96% in Q2 2026, buying an estimated $1.45M and bringing the position to 36,848 shares worth $3.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2608.

Fidelity Investments first reported a position in ANIP in Q1 2015 and has held it in 31 quarters since. The position peaked at $3.46M in Q2 2015. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Fidelity Investments held 36,848 shares of ANI Pharmaceuticals worth $3.05M as of Q2 2026.
  • Fidelity Investments bought 18,071 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.45M.
  • ANI Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2608 holding.
  • Fidelity Investments first reported a position in ANI Pharmaceuticals in Q1 2015 and has held it in 31 quarters since.
  • Fidelity Investments's ANI Pharmaceuticals position peaked at $3.46M in Q2 2015.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.